grant
EVALUATION OF IVO COMPOUNDS IN BLEOMYCIN-INDUCED PULMONARY FIBROSIS MODEL
Organization LEIDOS BIOMEDICAL RESEARCH, INC.Location FREDERICK, UNITED STATESPosted 15 Sept 2025Deadline 14 Sept 2027
NIHUS FederalResearch GrantFY2025BleoBleomycinEvaluationFunctional impairmentHumanIn-bleomycinLung InflammationLung Tissue FibrosisMiceMice MammalsModelingModern ManMurineMusPneumonitisPre-Clinical ModelPreclinical ModelsPulmonary FibrosisPulmonary InflammationReproducibilitydetermine efficacyefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacyfibrosis in the lungindium-bleomycinlung fibrosis
Full Description
To evaluate the efficacy of IVO compounds, the bleomycin-induced pulmonary fibrosis model in C57BL/6J
mice, the most well-characterized and widely used preclinical model of IPF, will be used. Bleomycin
administration results in reproducible pulmonary inflammation followed by fibrotic remodeling, leading
to functional impairments that recapitulate key aspects of human IPF.
Grant Number: 75N91019D00024-0-759102500022-1
NIH Institute/Center: NIH
Principal Investigator: lynn briscoe
Sign up free to get the apply link, save to pipeline, and set email alerts.
Sign up free →Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click